Show navigation Welcome to Orifarm Orifarm is an ambitious and progressive player in the healthcare business. Our ambition is to supply high quality and affordable pharmaceuticals and healthcare products. Together with our customers, and due to highly skilled employees, we have managed to do well during the years. Today, Orifarm is the largest supplier of parallel imported pharmaceuticals in Europe as well as a fast expanding supplier of generic products in this region. Read more. The journey continues For 25 years, Orifarm has been on a journey of growth, and the journey continues. For many years, parallel import of pharmaceuticals has been the principle part of our business. However, with the assets included in the acquisition from Takeda Pharmaceutical Company, we further expand our business within branded prescription and over-the-counter (OTC) pharmaceuticals, and enter into new categories such as vitamins, minerals, and food supplements (VMS). We also expand our business to new exciting markets and become one of the largest producers of OTC products in the Nordic countries. “The acquisition from Takeda Pharmaceutical Company is a real game changer to us as a company and to our employees. However, it also makes a huge difference for many of our customers and partners, as we are now looking forward to be able to supply a much broader product portfolio within pharmaceuticals, OTC and VMS products to our customers, partners, and eventually the end users." Erik Sandberg, CEO, Orifarm Group A game-changing acquisition In April 2020, Orifarm signed and announced the biggest acquisition in the history of the company. With the acquisition from Takeda Pharmaceutical Company Limited, we add more than 100 pharmaceuticals, OTC and VMS products to our product portfolio in Europe. Among these are well-known brands like Pamol, Kodimagnyl, Zymelin, Nycoplus, Apovit, and Amol. Orifarm has also acquired two additional production facilities in Hobro, Denmark, and Łyszkowice, Poland. In April 2021, approximately 600 employees transitioned to Orifarm at the closing of the transaction. Read more. Business as usual apply Integrating this game-changing acquisition naturally implies a lot of changes at our end, but for our existing customers, business as usual still applies. The order process and contact person remain the same until further notice, and new customers are welcomed with information on how to proceed our cooperation. FAQs We have put together some commonly asked questions to give you more information about The New Orifarm Healthcare. Why this acquisition? We used to be a trading company – what are we now? How does this affect the PI business set-up? What does the acquisition mean to our GE business? Orifarm acquires two new manufacturing sites, what does that mean to Viminco? What about our daily working life – will we see lots of changes? Contact us If you have any questions, please do not hesitate to contact us here. We look forward to presenting our expanded product portfolio and continuing this exciting journey together with you. Privacy Policy Cookies E-invoicing Healthcare Inspection report Find us on LinkedIn